- Home
- STK vs CRMD Comparison
STK vs CRMD Comparison
Compare STK & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.8M | 590.7M |
| IPO Year | 2009 | 2009 |
Fundamental Metrics
Financial Performance| Metric | STK | CRMD |
|---|---|---|
| Price | $53.85 | $7.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 41.2K | ★ 784.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.81 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $32.50 | $6.13 |
| 52 Week High | $58.46 | $13.02 |
Technical Indicators
Market Signals| Indicator | STK | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 65.63 | N/A |
| Support Level | $50.41 | N/A |
| Resistance Level | $55.53 | N/A |
| Average True Range (ATR) | 1.10 | 0.00 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 99.28 | 0.00 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.